GlassScriptPhysician profile
Abigail Gregory
NPI 1063880714
$7,904.90
in general payments reported to CMS, 2019-2025
27 companies · $2,112 in 2025
The $2,112 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,216 · 2022: $1,327 · 2023: $1,579 · 2024: $1,671 · 2025: $2,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,125 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,124.70 |
| Education | $236.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,017.29 | 2021-2025 | |
| Janssen Biotech, INC. | $945.86 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $945.61 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Lilly USA, LLC | $929.94 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $920.20 | 2021-2025 | |
| Ucb, INC. | $615.59 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $431.24 | 2021-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $304.38 | 2021-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $300.05 | 2022-2025 | Sotyktu |
| Amgen INC. | $237.13 | 2022-2025 | Otezla, Otezla |
| Pfizer INC. | $216.26 | 2021-2025 | |
| Genzyme Corporation | $171.25 | 2021-2025 | |
| Leo Pharma INC. | $167.17 | 2021-2023 | Adbry |
| Incyte Corporation | $160.63 | 2022-2025 | Opzelura |
| Vyne Pharmaceuticals INC. | $124.96 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.88 | 2023-2025 | Spevigo |
| Mayne Pharma Commercial LLC | $54.98 | 2021-2023 | |
| Kyowa Kirin, INC. | $50.24 | 2022-2024 | Poteligeo |
| Organogenesis INC. | $45.94 | 2022 | |
| Arcutis Biotherapeutics, INC. | $45.40 | 2023-2024 | Zoryve |
| Journey Medical Corporation | $29.79 | 2022-2023 | |
| Verrica Pharmaceuticals INC. | $24.21 | 2025 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.79 | 2025 | Cabtreo, Jublia, Siliq |
| Merz North America, INC. | $21.83 | 2024 | |
| Organon LLC | $19.75 | 2024 | |
| Ironwood Pharmaceuticals, INC | $13.73 | 2022 | |
| Biofrontera INC. | $8.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.